Moderna and CytomX partner for mRNA-based conditnionally activated therapeutics

Collaboration to generate and develop therapeutics for oncology and non-oncology conditions

World's first intranasal vaccine iNCOVACC will be rolled out in the fourth week of January

The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics

CEPI and SK bioscience partner to advance mRNA vaccine technology

CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus

Merck’s PREVYMIS effective for prevention of cytomegalovirus disease in adults post kidney transplantation

Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint

Merck and the Bill & Melinda Gates Medical Research Institute announce licensing agreement for tuberculosis antibiotic candidates

The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.

WHO, FAO, UNEP and WOAH launch One Health Joint Plan of Action

This first joint plan on One Health aims to create a framework to integrate systems and capacity so that we can collectively better prevent, predict, detect, and respond to health threats

Aster DM Healthcare signs Corporate TB Pledge

Periodic community awareness program through Aster’s DM Healthcare’s visual media and social media platforms and implementing TB control activity through Aster Pharmacies across South India

Thermo Fisher Scientific emphasizes on the need for more disruptive technologies

Thermo Fisher is working closely with large pharmaceutical businesses to develop companion diagnostics in multiple areas such as heart disease, neurosciences and infectious diseases.

ICON selected by BARDA to conduct anthrax vaccine clinical trial

This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.

AGC begins study to expand its Bio-CDMO capability in Japan